Results 11 to 20 of about 1,694,367 (292)

Marine-derived protein kinase inhibitors for neuroinflammatory diseases

BioMedical Engineering OnLine, 2018
Neuroinflammation is primarily characterized by overexpression of proinflammatory mediators produced by glial activation or immune cell infiltration. Several kinases have been shown to be critical mediators in neuroinflammation. One of the largest groups
Chong Ning, Hui-Min David Wang, Rong Gao, Yu-Chia Chang, Fengqing Hu, Xianjun Meng, Shi-Ying Huang   +6 more
doaj   +2 more sources

Small molecule tyrosine kinase inhibitors in pancreatic cancer

Biologics: Targets & Therapy, 2008
Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for ...
Sachin Gupta, Bassel F El-Rayes
doaj   +1 more source

Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulation [PDF]

, 2014
Casein kinase 2 (protein kinase CK2) is a conserved eukaryotic serine/theronine kinase with multiple substrates and roles in the regulation of cellular processes such as cellular stress, cell proliferation and apoptosis.
Schmid, Ralf, Solyakov, Lev, Doerig, Christian, Graciotti, Michele, Burley, Glenn, Tobin, Andrew B, Cullis, Paul, Alam, Mahmood, Bottrill, Andrew R   +8 more
core   +3 more sources

High Throughput Screens Yield Small Molecule Inhibitors of Leishmania CRK3:CYC6 Cyclin-Dependent Kinase [PDF]

, 2011
Background: Leishmania species are parasitic protozoa that have a tightly controlled cell cycle, regulated by cyclin-dependent kinases (CDKs). Cdc2-related kinase 3 (CRK3), an essential CDK in Leishmania and functional orthologue of human CDK1, can form ...
Walker, Roderick G., Brown, Elaine, Thomson, Graeme, Blake, David G., Malone, Kirk, Turner, Nicholas J., Grant, Karen, Mottram, Jeremy C., Walkinshaw, Malcolm D., Nowicki, Matthew W.   +9 more
core   +3 more sources

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome. [PDF]

PLoS ONE, 2017
Protein kinases are critical drug targets for treating a large variety of human diseases. Type-III kinase inhibitors have attracted increasing attention as highly selective therapeutics.
Zheng Zhao, Lei Xie, Philip E Bourne
doaj   +1 more source

Second‐line therapy with first‐ or second‐generation tyrosine kinase inhibitors in EGFR‐mutated non‐small cell lung cancer patients with T790M‐negative or unidentified mutation

Thoracic Cancer, 2021
Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura, Tomohito Okano, Masahiro Naito, Soichi Iwanaka, Ayaka Ohiwa, Yasumasa Sakakura, Taro Yasuma, Hajime Fujimoto, Corina N. D'Alessandro‐Gabazza, Yasuhiro Oomoto, Tetsu Kobayashi, Esteban C. Gabazza, Hidenori Ibata   +12 more
doaj   +1 more source

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

Haematologica, 2014
The phosphoinositide 3-kinase pathway represents an important anticancer target because it has been implicated in cancer cell growth, survival, and motility. Recent studies show that PI3K may also play a role in the development of resistance to currently
Elias Jabbour, Oliver G. Ottmann, Michael Deininger, Andreas Hochhaus   +3 more
doaj   +1 more source

High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase [PDF]

, 2011
<p><b>Background:</b> <i>Leishmania</i> species are parasitic protozoa that have a tightly controlled cell cycle, regulated by cyclin-dependent kinases (CDKs).
Mottram Jeremy C., Thomson, Graeme, Mottram, JC, Grant Karen M., Turner, N.J., Malcolm D. Walkinshaw, Malone, Kirk, Turner, Nicholas J., Nicholas J Turner, Jeremy C. Mottram, Karen M. Grant, Walker, Roderick G., Kita, K, Graeme Thomson, Malone Kirk, Karen M Grant, Grant, Karen, Nicholas J. Turner, Walker, RG, Nowicki, Matthew W., Thomson Graeme, Walkinshaw, M.D., Walkinshaw Malcolm D., David G. Blake, David G Blake, Walker Roderick G., Brown, Elaine, Brown Elaine, Blake David G., Brown, E, Malone, K, Turner Nicholas J., Walkinshaw, MD, Blake, DG, Matthew W. Nowicki, Walker, R.G., Malone, K., Blake, David G., Elaine Brown, Mottram, J.C., Kirk Malone, Walkinshaw, Malcolm D., Matthew W Nowicki, Nowicki, MW, Brown, E., Nowicki Matthew W., Turner, Nicholas J.; id_orcid, Grant, Karen M., Grant, K.M., Mottram, Jeremy C., Roderick G Walker, Thomson, G, Jeremy C Mottram, Roderick G. Walker, Nowicki, M.W., Grant, KM, Blake, D.G., Malcolm D Walkinshaw, Turner, NJ, Thomson, G.   +59 more
core   +2 more sources

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Journal for ImmunoTherapy of Cancer, 2019
Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh, Joycelyn Lee, Gloria Chan, Cheng Ean Chee, Su Pin Choo   +4 more
doaj   +1 more source

Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. [PDF]

, 2013
Current inhibitors of angiogenesis comprise either therapeutic antibodies (e.g. bevacicumab binding to VEGF-A) or small molecular inhibitors of receptor tyrosin kinases like e.g. sunitinib, which inhibits PDGFR and VEGFR.
Gucký, Tomáš, Stefan Zahler, Krystof, Vladimir, Strnad, Miroslav, Liebl, Johanna, Vollmar, Angelika M., Fürst, Robert, Vladimir Krystof, Robert Fürst, Sabine B Weitensteiner, Miroslav Strnad, Johanna Liebl, Havlíček, Libor, Tomáš Gucký, Weitensteiner, Sabine B., Zahler, Stefan, Libor Havlíček, Angelika M Vollmar   +17 more
core   +2 more sources